agil post strong top bottom beat aid resili pharma trend
signific bounc back china expect april/may repres bottom
busi y/i set compel favor lsag comparison
continu momentum across key growth area pharma acg nasd cell analysi
long term outlook remain excit p-t
core revenu declin y/i significantli expect consensu
y/i declin rel forecast nearli everi piec busi exceed
expect notabl upsid came china y/i vs guidanc
y/i declin acg hsd y/i pharma y/i even exclud y/i tailwind
test revenu still notabl expect perhap
encouragingli april revenu declin y/i aid y/i growth china
impli y/i declin ex-china page detail
gross margin came consensu adjust oper margin
came nearli consensu strong revenu margin result ep
consensu
manag provid rang scenario revenu expect core
revenu declin y/i manag also note expect may revenu
trend similar april y/i cautiou guidanc make sens assum april/
may bottom revenu appear like reach least high end rang
adjust model accordingli assum continu improv trend
throughout cours
much pick updat near term result much better
expect importantli long term outlook remain excit agil appear
well posit post peer averag top bottom line growth long term
excit set favor lsag comparison continu strong pharma
acg nasd cell analysi momentum exit lasergen develop
provid potenti bottom line leverag expect agil continu
cleanest balanc sheet group net leverag revis price
target base dcf analysi repres ep forecast
pleas see page report import disclosur
continu view agil posit competit perspect continu
believ compani post averag revenu earn growth
forese futur contrari peer agil still multipl avenu upsid outsid
core oper buybacks/m tax rate like long-term outlook though
near term import note agil peer averag exposur industrial/
cyclic end market rate share outperform price target base dcf
ep growth continu approxim
low mid teen
agil acquir larger
organ revenu growth acceler
materi expect
possibl addit
lack growth render multipl high
growth lower expect china
expect margin expans fail
life scienc diagnost chemic analysi compani
compani current oper segment life scienc appli market lsag
diagnost genom dgg agil crosslab group acg
compani report thomson eikon cowen compani
cowen vs consensu mm except re-affirmed core fx agross flat y/i re-affirmed op re-affirmed segment metric mm except growth growth growth statement mm except growth currenc margin per count consensu growth revenu came consensu core revenu declin y/i well ahead consensu declin rel model everi segment perform much better expect april revenu y/i repres bottom manag also note y/i revenu tailwind test quarter end market pharma highlight post core growth chemical/energi acc/gov y/i though better expect surprisingli food revenu grew quarter encourag gross margin came forecast though line ep came consensu clean top bottom beat streetaccount consensu lsag revenu came consensu core revenu y/i manag note growth biopharma china china food cell analysi off-set doubl digit declin academic/gov margin also well ahead fear interestingli cell analysi abl grow msd y/i despit high proport academic/gov mix streetaccount consensu acg revenu came ahead consensu nearli forecast manag note acg growth would sever point stronger delay instal sever instrument acg increas hsd y/i china despit end market growth driven biopharma environmental/forens off-set declin end market due headwind oper margin significantli expect like aid product mix less demand servic streetaccount consensu dgg revenu came consensu core growth significantli expect manag note y/i growth nasd resili patholog trend us declin eu grew dgg also like benefit modest tailwind bravo liquid handl oem antibodi busi margin strong like aid reduc lasergen spend partial quarter oper margin came nearli consensu clean top bottom expens line sg came forecast despit significantli higher expect revenu cowen
compani report cowen compani
mm except per share datajan net guidanc withdrawn net core fx arevenu acq currenc contribut adjust segmentlif scienc appli group flat y/i core growth re-affirmed currenc contribut adjust crosslab group hsd y/i currenc contribut adjust genom group hsd-ldd y/i currenc contribut adjust hsd y/i currenc lsd y/i currenc pacif lsd-msd y/i includ china lsd-msd y/i currenc end marketpharma hsd y/i expect y/i growth add overal pharmareport flat y/i msd y/i lsd y/i flat y/i msd y/i cowen
compani report thomson eikon cowen compani
mm except per share datajan guidanc withdrawn core fx aorgan guidanc withdrawn flat y/i gener oper non-oper combin net interest/oth re-affirmed net interest earn per guidanc withdrawn expectationsjan gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit macroeconom deterior
current level challeng china eros market share price due competit
inabl deliv incremental/decrement margin target value-destruct
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc may et dissemin may et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
